MX2024000908A - Metodo para producir derivado de arilamida. - Google Patents
Metodo para producir derivado de arilamida.Info
- Publication number
- MX2024000908A MX2024000908A MX2024000908A MX2024000908A MX2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A
- Authority
- MX
- Mexico
- Prior art keywords
- arylamide derivative
- fluoropyridin
- amino
- pharmaceutically acceptable
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021120977 | 2021-07-21 | ||
| PCT/JP2022/028187 WO2023003014A1 (ja) | 2021-07-21 | 2022-07-20 | アリールアミド誘導体の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000908A true MX2024000908A (es) | 2024-02-07 |
Family
ID=84980009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000908A MX2024000908A (es) | 2021-07-21 | 2022-07-20 | Metodo para producir derivado de arilamida. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240327355A1 (enExample) |
| EP (1) | EP4375273A4 (enExample) |
| JP (2) | JP7268255B1 (enExample) |
| KR (1) | KR102671612B1 (enExample) |
| CN (1) | CN117677607A (enExample) |
| AR (1) | AR126517A1 (enExample) |
| AU (1) | AU2022312992A1 (enExample) |
| CA (1) | CA3226827A1 (enExample) |
| IL (1) | IL310123A (enExample) |
| MX (1) | MX2024000908A (enExample) |
| TW (1) | TW202321198A (enExample) |
| WO (1) | WO2023003014A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025007811A1 (zh) * | 2023-07-06 | 2025-01-09 | 成都华健未来科技有限公司 | 一类芳香酰胺类衍生物及其用途 |
| WO2025146040A1 (zh) * | 2024-01-01 | 2025-07-10 | 华健未来（成都）科技股份有限公司 | 芳香酰肼类衍生物及其医药用途 |
| CN118604164B (zh) * | 2024-05-15 | 2025-06-06 | 石家庄四药有限公司 | 一种非奈利酮中间体中杂质的检测方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200520745A (en) * | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| JP2016034900A (ja) * | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法 |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| JPWO2022018875A1 (enExample) * | 2020-07-22 | 2022-01-27 | ||
| BR112023000883A2 (pt) * | 2020-07-22 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Composição contendo derivado de arilamida |
-
2022
- 2022-07-20 WO PCT/JP2022/028187 patent/WO2023003014A1/ja not_active Ceased
- 2022-07-20 CA CA3226827A patent/CA3226827A1/en active Pending
- 2022-07-20 US US18/579,949 patent/US20240327355A1/en active Pending
- 2022-07-20 MX MX2024000908A patent/MX2024000908A/es unknown
- 2022-07-20 IL IL310123A patent/IL310123A/en unknown
- 2022-07-20 CN CN202280050524.4A patent/CN117677607A/zh active Pending
- 2022-07-20 EP EP22845947.5A patent/EP4375273A4/en active Pending
- 2022-07-20 AU AU2022312992A patent/AU2022312992A1/en active Pending
- 2022-07-20 TW TW111127162A patent/TW202321198A/zh unknown
- 2022-07-20 KR KR1020237036428A patent/KR102671612B1/ko active Active
- 2022-07-20 AR ARP220101914A patent/AR126517A1/es unknown
- 2022-07-20 JP JP2022563493A patent/JP7268255B1/ja active Active
-
2023
- 2023-04-20 JP JP2023069597A patent/JP2023084138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL310123A (en) | 2024-03-01 |
| AU2022312992A1 (en) | 2024-02-29 |
| JP2023084138A (ja) | 2023-06-16 |
| US20240327355A1 (en) | 2024-10-03 |
| CN117677607A (zh) | 2024-03-08 |
| JPWO2023003014A1 (enExample) | 2023-01-26 |
| KR20230152797A (ko) | 2023-11-03 |
| TW202321198A (zh) | 2023-06-01 |
| KR102671612B1 (ko) | 2024-05-31 |
| CA3226827A1 (en) | 2023-01-26 |
| AR126517A1 (es) | 2023-10-18 |
| EP4375273A1 (en) | 2024-05-29 |
| WO2023003014A1 (ja) | 2023-01-26 |
| EP4375273A4 (en) | 2025-05-21 |
| JP7268255B1 (ja) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000908A (es) | Metodo para producir derivado de arilamida. | |
| CL2023000199A1 (es) | Composición que contiene un derivado de arilamida | |
| CL2021000737A1 (es) | Fabricación de compuestos y composiciones para inhibir la actividad de shp2 | |
| AR117101A1 (es) | Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras | |
| AR114631A1 (es) | Métodos e intermedios para preparar compuestos de piridina | |
| MX2021006908A (es) | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. | |
| CR20220390A (es) | Derivados de arilamida con actividad antitumoral | |
| CO2021012375A2 (es) | Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo | |
| CU24735B1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| ECSP088830A (es) | Compuestos de benzoxazole y benzotiazole sustituidos-6-o y métodos para inhibir la señalización csf-1r | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| ECSP088267A (es) | Un procedimiento mejorado para preparar compuestos de aminodiol protegidos con oxazodilina, utiles como intermediarios para el florfenicol | |
| MX2021012750A (es) | Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo. | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| MX2018013565A (es) | Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales. | |
| NZ602710A (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| MX2023011176A (es) | Tratamiento de hidradenitis supurativa con orismilast. | |
| MX2022006910A (es) | Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico. | |
| CO2022015976A2 (es) | Síntesis de intermedios de vinil ciclobutilo | |
| BR112023018246A2 (pt) | Formas de sal e sólidas de um inibidor de cinase | |
| BR112020020549A8 (pt) | Novo processo para síntese de um composto fenoxi diaminopirimidina | |
| ES2421605T3 (es) | Inhibidores de trastorno isquémico o enfermedades | |
| UY39026A (es) | Proceso químico para la síntesis de compuestos de piridazina sustituida | |
| AR093257A1 (es) | Compuestos insecticidas | |
| MX2019015849A (es) | Nuevos compuestos de espirolactona. |